Business Wire

CÆLUM-CAPITAL

Share
London-Based Cælum Capital Limited Invests in Pioneering Scotch Whisky Business – Compass Box

Cælum Capital Limited, a specialist investor focused on premium beverage businesses, announced the acquisition of a majority stake in Compass Box Delicious Whisky Limited, a London-based premium Scotch whisky brand. Compass Box is ranked 4th in the “Top Trending Brands” in Scotch whisky segment by Drinks International.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005290/en/

Cælum was set up by Manish Rungta, an ex-Diageo executive with a background in private equity. Cælum has brought in Maurice Doyle as the new CEO of Compass Box to partner with the Founder, John Glaser, in the continued development of the business. A spirits industry veteran, Maurice Doyle brings nearly 30 years of marketing, commercial, and executive leadership experience from within the global alcoholic beverages sector. “I am delighted to be joining Compass Box. It is a brand that I have long admired as a pioneer within Scotch whisky. I have a huge amount of respect for John and what he has achieved,” says Doyle.

Founded in London in 2000, Compass Box is a reflection of Glaser’s personal vision for what the future of whisky making should be. John Glaser was named by Whisky Advocate as one of the “Thirty Innovators Who Shaped Today’s Whisky” and one of the only Two alive today. “With Maurice joining me at the helm, we are excited to double-down on our determination to democratise the enjoyment of Scotch whisky, to continue releasing products that reveal the creative art behind blending,” says Glaser, who has described the Compass Box mission as, “fighting…what I call the ‘single malt hegemony.’”

Cælum investment will be used to strengthen the balance sheet of the Company, acquire inventory, and build production facilities. Cælum will help facilitate the ambition of Compass Box to provide more opportunities to explore, experiment and innovate, with curiosity and creativity as its guiding principles. Manish Rungta, the Managing Partner at Cælum said, “We are excited to partner with Compass Box and it is representative of the innovative and pioneering brands within the beverage category that we would like to invest behind.”

Metric Point Capital, acted as the exclusive financial advisor and placement agent to Cælum. “We are thankful for the support of the Metric Point team during a very complex process and a crowded North American fundraising market. Metric Point brought highly technical skillsets and a tailored solution for this unique proprietary deal and we ended up being oversubscribed in our fundraising,” said Manish Rungta.

Corporate Partner Tom Braiden led the team at Brown Rudnick, an international law firm, which acted as exclusive legal advisor to Cælum.

Cælum Capital Limited
Cælum Capital Limited is based in London and is a specialist investor focused on investing in premium beverage businesses based in North America and Europe with a focus on alcoholic beverages. Cælum was founded by Manish Rungta, who is the Managing Partner of the firm and has extensive investment experience in the beverage sector, both alcoholic and non-alcoholic. Ex-SABMiller executive Mark Eames has joined Cælum as an Operating Partner and has extensive strategic, operational, and financial planning experience within the beverage sector. Cælum targets opportunities in the beverage segment with investment amounts ranging from US$50 – 200 million. For more information, please visit www.caelumcap.co.uk .

Compass Box
Compass Box are Scotch whiskymakers. The word ‘whiskymaker’ is their word – it does not appear in a dictionary. For over 20 years they have been relentlessly focused on reinventing Scotch whisky, with every new blend designed to help make the world of whisky a more interesting place. Compass Box have won more awards for innovation than any other producer in Scotland because they are always experimenting. Always looking for sparks of creativity that will deliver something totally compelling, yet completely surprising. This vision motivates them as whiskymakers. Their blends are consistently rated equal to or better than the great single malts of Scotland by the most respected voices in the industry. For more information, please visit www.compassboxwhisky.com or @CompassBoxWhiskyCo on Instagram.

Metric Point Capital (Member FINRA and SIPC)
Metric Point Capital is a boutique private capital advisory firm specializing in raising institutional capital for alternative investment managers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye